ICS Global Limited, an investment holding company, provides medical billing services primarily in the United Kingdom.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.19|
|52 Week High||AU$1.62|
|52 Week Low||AU$2.35|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||18.38%|
|3 Year Change||113.66%|
|5 Year Change||41.29%|
|Change since IPO||-95.88%|
Recent News & Updates
Should You Buy ICS Global Limited (ASX:ICS) For Its Dividend?
Today we'll take a closer look at ICS Global Limited ( ASX:ICS ) from a dividend investor's perspective. Owning a...
Is ICS Global Limited's (ASX:ICS) Latest Stock Performance A Reflection Of Its Financial Health?
ICS Global (ASX:ICS) has had a great run on the share market with its stock up by a significant 23% over the last three...
|ICS||AU Healthcare||AU Market|
Return vs Industry: ICS underperformed the Australian Healthcare industry which returned 20.3% over the past year.
Return vs Market: ICS underperformed the Australian Market which returned 25.6% over the past year.
Stable Share Price: Insufficient data to determine ICS's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine ICS's volatility change over the past year.
About the Company
ICS Global Limited, an investment holding company, provides medical billing services primarily in the United Kingdom. The company offers medical billing and collection services to medical consultants and specialists. ICS Global Limited was incorporated in 1996 and is based in Sydney, Australia.
ICS Global Fundamentals Summary
|ICS fundamental statistics|
Is ICS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ICS income statement (TTM)|
|Cost of Revenue||AU$42.87k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.14|
|Net Profit Margin||0.00%|
How did ICS perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is ICS Global undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ICS (A$2.19) is trading above our estimate of fair value (A$0.96)
Significantly Below Fair Value: ICS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ICS is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: ICS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICS is good value based on its PB Ratio (1x) compared to the AU Healthcare industry average (1.8x).
How is ICS Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ICS Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has ICS Global performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICS is currently unprofitable.
Growing Profit Margin: ICS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ICS is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.
Accelerating Growth: Unable to compare ICS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (82.1%).
Return on Equity
High ROE: ICS has a negative Return on Equity (-6.27%), as it is currently unprofitable.
How is ICS Global's financial position?
Financial Position Analysis
Short Term Liabilities: ICS's short term assets (A$23.0M) exceed its short term liabilities (A$154.1K).
Long Term Liabilities: ICS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ICS is debt free.
Reducing Debt: ICS had no debt 5 years ago.
Debt Coverage: ICS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ICS has no debt, therefore coverage of interest payments is not a concern.
What is ICS Global current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ICS's dividend (1.83%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.19%).
High Dividend: ICS's dividend (1.83%) is low compared to the top 25% of dividend payers in the Australian market (5.15%).
Stability and Growth of Payments
Stable Dividend: ICS has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ICS's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: ICS is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
ICS Global has no CEO, or we have no data on them.
Experienced Board: ICS's board of directors are seasoned and experienced ( 11.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ICS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ICS Global Limited's employee growth, exchange listings and data sources
- Name: ICS Global Limited
- Ticker: ICS
- Exchange: ASX
- Founded: 1996
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$23.223m
- Shares outstanding: 10.60m
- Website: https://icsglobal.com.au
- ICS Global Limited
- 20 Bond Street
- Suite 3.03
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/15 21:51|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.